Login

Cambridge Antibody Technologies, Inc.

Description

Cambridge, U.K.; acquired by AstraZeneca for $13 billion in mid-2006

Related product monographs:

  1. Anthrax Mab, rDNA/HGSI
  2. B-cell-activating factor Mab, rDNA
  3. IL-12/23 Mab, rDNA/Abbott
  4. Kallikrein inhibitor, rDNA
  5. RSV Mab, rDNA
  6. TNF Mab, rDNA, human/Abbott

Location

Cambridge UK FOR

Reference Number

9521

Location

  • BioPlan Associates, Inc.
  • One Research Court, Suite 450
  • Rockville, MD 20850

Contact Info

  • Copyright © 2023 BioPharma